RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
425 articles with RedHill Biopharma
-
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
8/17/2022
RedHill Biopharma today announced that the European Commission has granted Orphan Drug Designation to RHB-2041 for the treatment of nontuberculous mycobacteria (NTM) disease.
-
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
7/12/2022
RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.'s leading brand for Helicobacter pylori (H. pylori) eradication treatment - invitation sent to researchers with significant recently published clinical findings.
-
RedHill announced that it will lay off a third of its U.S. workforce in an effort to save money over the next year and a half.
-
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
6/23/2022
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22.
-
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
6/17/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
-
RedHill Presents New Talicia® Data Analyses at DDW 2022
5/25/2022
RedHill Biopharma Ltd. announced the presentation of two new data analyses from the Talicia® H. pylori eradication clinical trials program at Digestive Diseases Week 2022.
-
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
5/9/2022
RedHill Biopharma Ltd. today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs").
-
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
4/11/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.
-
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
4/11/2022
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640).
-
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
3/17/2022
RedHill Biopharma Ltd. today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea
3/15/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd., a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.
-
RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022
3/10/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven
2/17/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited preliminary financial data.
-
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
1/13/2022
RedHill Biopharma Ltd. today announced new data from a prespecified analysis of all oral opaganib's[1] Phase 2/3 study patients with positive PCR at screening, demonstrating that opaganib improved the median time to viral RNA clearance by at least 4 days.
-
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
-
RedHill Announces Additional Insider Buying
12/15/2021
RedHill Biopharma Ltd. today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHill since mid-October, 2021, in open-market transactions.
-
RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori
12/9/2021
RedHill Biopharma Ltd. today announced the publication in the journal Digestive Diseases and Sciences.
-
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication
12/9/2021
RedHill Biopharma today announced the publication in the journal Digestive Diseases and Sciences.
-
RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
12/6/2021
RedHill Biopharma Ltd. today announced that because opaganib's[1] proposed mechanism of action is not impacted by spike protein mutations, opaganib is expected to be unaffected by mutations associated with Omicron and other known variants of concern.